TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

Enzyme Replacement Therapy Medicines

Pharmaceutical products
Scotland (UKM)
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS"): "Enzyme Replacement Therapy Medicines". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityThe Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")Scope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS"). These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
9.9Bids / Report
23.4% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 974 active published awards; 798 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityThe Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSFramework
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published15 Aug 2024, 11:45 BST
Last source update15 Aug 2024, 11:45 BST
Recurring procurementNot published
ClassificationPharmaceutical products
Delivery area
Scotland (UKM)
OCIDocds-h6vhtk-047915
What is being bought
Supply of Enzyme Replacement Therapy Medicines (a-d) to NHS Scotland: - NP92624(a) Laronidase 500units/5ml solution for infusion vials 1 vial (Aldurazyme®) - NP92624(b) Imiglucerase 400unit powder for solution for infusion vials 1 vial (Cerezyme®) - NP92624(c) Agalsidase beta 35mg powder for solution for infusion vials 1 vial (Fabrazyme®) - NP92624(c) Agalsidase beta 5mg powder for solution for infusion vials 1 vial (Fabrazyme®) - NP92624(d) Alglucosidase alfa 50mg powder for solution for infusion vials 1 vial (Myozyme®)
What changed
From the official release history
  1. Official notice release published
    15 Aug 2024, 11:45 BST
  2. Buyer information updated
    15 Aug 2024, 11:45 BST
  3. Status changed to complete
    2 Jul 2024, 12:52 BST
  4. Official notice release published
    2 Jul 2024, 12:52 BST
  5. Buyer information updated
    2 Jul 2024, 12:52 BST
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    cancelled
    Published valueNot published
    The Framework Agreement is for the supply of Enzyme Replacement Therapy Medicines (a-d: Aldurazyme®/ Cerezyme®/ Fabrazyme®/ Fabrazyme®/ Myozyme®) to NHS Scotland. The Authority has awarded this framework as a Single supplier framework agreement to one (1) Framework Participant.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    15 Aug 2024, 11:45 BST
  2. Award active
    Not published · Not published
  3. Contract active
    Signed 18 Jul 2024, 00:00 BST · £12,437,853
Commercial outcome and competition
Awards
Aventis Pharma Ltd Trading As Sanofi
Not published · Not published · active
Contracts
Contract
£12,437,853 · signed 18 Jul 2024, 00:00 BST · active
Bid statistics
bids: 1 (lot 1)
electronicBids: 1 (lot 1)
foreignBidsFromEU: 0 (lot 1)
foreignBidsFromNonEU: 1 (lot 1)
smeBids: 0 (lot 1)
Buyer and organisations in this procedure

The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")

Contracting authority GB-FTS-322
View buyer profile

  • The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
    buyer
    centralPurchasingBody

    Gyle Square (NSS Head Office), 1 South Gyle Crescent, Edinburgh, UKM, EH12 9EB
    michelle.semple3@nhs.scot

  • Aventis Pharma Ltd Trading As Sanofi
    supplier

    410 Thames Valley Park Drive, Reading, UK, RG6 1PT
    +44 1183543118

  • Sheriff Court House
    reviewBody

    27 Chambers Street, Edinburgh, EH1 1LB
    edinburgh@scotcourts.gov.uk
    +44 1312252525
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationaleThe medicine to be awarded to the framework agreement is protected by exclusive rights, including intellectual property rights, in line with Regulation 33(1)(b)(iii) of the Public Contracts (Scotland) Regulations 2015.